Software

Solium Capital is undervalued, says Euro Pacific analyst Andrej Krneta

The market is mispricing Solium Capital’s (TSX:SUM) potential, says Euro Pacific Canada analyst Andrej Krneta.

Today, after market, Solium will report its fourth quarter and fiscal 2014 results. Krneta expects that the company’s fourth quarter revenue will grow 10.7% year-over-year to $19.2-million, slightly lower than street consensus of $19.6-million. He thinks Solium will remain at the high end of its own EBITDA target of 20-25%.

The analyst says he is looking for clarity on the company’s international expansion plans.

“We expect organic growth in Canada with the US subdued due to the ever-present competitive pressures,” he said. “The rollout in the UK remains ongoing, but a surge in seats served through its white-labelling is unlikely. Thus, much of the focus should stay outside of North America”.

Krneta says that with uptake slower than expected in the UK, the Australian market remains a viable option for the company.

In a research update to clients yesterday, Krneta maintained his “Buy” rating and one-year target of $9.50 on Solium Capital, implying a return of 19% at the time of publication. He says further upside could come from a “more aggressive approach to capital allocations”, and thinks the current valuation is mispricing the company’s growth potential.

At press time, shares of Solium Capital were down 2% to $6.77.

Tagged with: sum
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Verano Holdings is undervalued, Haywood says

Haywood Capital Markets analyst Neal Gilmer says Verano Holdings (Verano Holdings Stock Quote, Chart, News, Analysts, Financials NEO:VRNO) is staying… [Read More]

2 days ago

Knight Therapeutics is a buy, Stifel says

Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSXV:GUD) is continuing to build momentum, according to Stifel Nicolaus… [Read More]

2 days ago

Groupon wins price target raise at Roth

Roth Capital Partners has raised its price target on Groupon (Groupon Inc Stock Quote, Chart, News, Analysts, Financials NASDAQ:GRPN) to… [Read More]

2 days ago

Trulieve Cannabis is a buy, Beacon says

Trulieve Cannabis (Trulieve Cannabis Stock Quote, Chart, News, Analysts, Financials CSE:TRUL) delivered a strong start to fiscal 2025, beating high-end… [Read More]

2 days ago

Green Thumb Industries should be a core holding for cannabis investors, analyst says

Green Thumb Industries (Green Thumb Industries Stock Quote, Chart, News, Analysts, Financials CSE:GTII) delivered a steady first quarter and remains… [Read More]

2 days ago

5N Plus just delivered an “exceptional” quarter, this analyst says

5N Plus (5N Plus Stock Quote, Chart, News, Analysts, Financials TSX:VNP) blew past expectations in the first quarter of 2025,… [Read More]

2 days ago